Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer

This study aimed to evaluate the biological functions of excision repair cross complementation goup 1 (ERCC1) in cell proliferation, cell cycle, invasion and cisplatin response of non-small cell lung cancer (NSCLC) cells. Firstly, ERCC1 gene was successfully transfected into H1299 cells by gene clon...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of oncology 2015-02, Vol.46 (2), p.809-817
Hauptverfasser:	WANG, SHOUFENG, PAN, HONG, LIU, DESEN, MAO, NAIQUAN, ZUO, CHUANTIAN, LI, LI, XIE, TONG, HUANG, DINGMING, HUANG, YAOYUAN, PAN, QI, YANG, LI, WU, JUNWEI
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers Cancer Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Cell culture Cell cycle Cell growth Cell Line, Tumor Cell Proliferation - drug effects Cell Proliferation - genetics Chemotherapy Cisplatin Cisplatin - administration & dosage cisplatin resistance Cloning Deoxyribonucleic acid DNA DNA repair DNA-Binding Proteins - antagonists & inhibitors DNA-Binding Proteins - biosynthesis Drug resistance Drug Resistance, Neoplasm - genetics Drug therapy Endonucleases - antagonists & inhibitors Endonucleases - biosynthesis excision repair cross complementation group 1 Gene Expression Regulation, Neoplastic - drug effects Genetic aspects Health aspects Humans Lung cancer Lung cancer, Non-small cell Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Medical prognosis Multidrug Resistance-Associated Proteins - biosynthesis Neoplasm Invasiveness - genetics non-small cell lung cancer Patients Physiology Prognosis Proteins RNA, Small Interfering Studies Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!